Chapter II: Donation and use of elements and products of the human body.

Title I of Book II of this Part is applicable in New Caledonia and French Polynesia, in the wording resulting from Law no. 2016-41 of 26 January 2016 on the modernisation of our healthcare system, subject to the following adaptations: 1° Articles L. 1211-2, L. 1211-3 with the exception of its second paragraph, and L. 1211-6-1 are applicable in their wording resulting from Law no. 2021-1017 of 2 August 2021….

Article L. 1220-1 and Chapter I of Title II of Book II of this Part are applicable in New Caledonia and French Polynesia, with the exception of articles L. 1221-2, L. 1221-8-2, L. 1221-9, L. 1221-10-1, and L. 1221-13, and subject to the adaptations provided for in this Chapter. Article L. 1221-5 is applicable in French Polynesia in the version resulting from Law no. 2021-1017 of 2 August 2021. Article…

For their application in New Caledonia and French Polynesia: 1° In Article L. 1221-3, the words: “under conditions laid down by decree” do not apply ; 2° In article L. 1221-4, the last paragraph is not applicable. 2° bis In Article L. 1221-10, the first paragraph, the third paragraph and the last paragraph do not apply and, in the penultimate paragraph, the words: “1° to 3°” are replaced by the…

The Etablissement français du sang instituted in Chapter II of Title II of Book II of this Part may enter into technical cooperation agreements with the authorities of New Caledonia or French Polynesia. In particular, an agreement may specify the terms and conditions under which the insurance taken out by the Etablissement Français du Sang against the risks incurred by donors as a result of collection operations covers the liability,…

Title III of Book II of this Part is applicable in New Caledonia and French Polynesia, with the exception of articles L. 1231-1 A, L. 1233-3, L. 1233-4, L. 1234-3-1, L. 1234-4, L. 1235-1, with the exception of the last paragraph, L. 1235-5 and L. 1235-7 and subject to the adaptations provided for in this chapter. Articles L. 1231-1, L. 1231-3 and L. 1231-4 are applicable in French Polynesia in…

For their application in New Caledonia and French Polynesia: 1° In Article L. 1231-1, V does not apply ; 2° In the first paragraph of Article L. 1231-3, the words “Minister of Health” are replaced by the words “Representative of the State in New Caledonia or French Polynesia, taken after consultation with the health authorities of New Caledonia and French Polynesia”; 3° Article L. 1231-4 reads as follows: Art. L….

Title IV of Book II of this Part is applicable in New Caledonia and French Polynesia, with the exception of Articles L. 1242-3, L. 1243-1, L. 1243-2-1, L. 1243-5 to L. 1243-9, L. 1244-1-1, L. 1244-1-2, L. 1244-5, L. 1245-6 and subject to the adaptations provided for in this chapter. Article L. 1241-1 is applicable there in the version resulting from Order no. 2022-1086 of 29 July 2022. Articles L….

For their application in New Caledonia and French Polynesia: 1° In Article L. 1241-1, the words: “by the Agence nationale de sécurité du médicament et des produits de santé pursuant to 1° of Article L. 5311-2” are replaced by the words: “in accordance with the conditions laid down by local regulations having the same purpose” ; 2° In the last paragraph of Article L. 1241-3, the words: “in particular with…

For their application in New Caledonia and French Polynesia : 1° The first three paragraphs of Article L. 1243-2 are replaced by the following paragraph: In order to be authorised to ensure the preparation, conservation, distribution and transfer, for autologous or allogeneic therapeutic purposes, of tissues and their derivatives and cell therapy preparations, health establishments must operate in accordance with the principles set out in Title I of this book….

For their application in New Caledonia and French Polynesia : a) In Article L. 1245-1, the last two paragraphs do not apply ; b) Article L. 1245-5 is replaced by the following provisions: Art.L. 1245-5.- Only persons whose activity involves medical biology examinations, anatomical cytopathology examinations, legal expertise or quality control or assessment, in particular of in vitro diagnostic medical devices, may import or export biological samples. Only organisations authorised…